FDA, Medical Communications, and Intended Use—A New Challenge to First and Fifth Amendment Constraints on Government Power (Open Access)
Food and Drug Law Journal | Volume 78 | Number 3
Nutraceuticals and Social Media: FDA and FTC Like and Subscribe to the Next Big Trend in Litigation
Food and Drug Law Journal | Volume 78 | Number 3
Orphan Does Not Always Mean Alone—A Case Study of Eosinophilic Esophagitis, an Orphan Disease
Food and Drug Law Journal | Volume 78 | Number 3
Federal Preemption and the Post-Dobbs Reproductive Freedom Frontier (Open Access)
Food and Drug Law Journal | Volume 78 | Number 2
Enhanced Engagement: The Evolving Relationship between FDA and DoD Regulatory Authorities (Open Access)
Food and Drug Law Journal | Volume 78 | Number 2
Generic Substitution Laws and Combination Products
Food and Drug Law Journal | Volume 78 | Number 2
Parallel Enforcement: SEC Authorities and How They Can Impact FDA’s Civil and Criminal Enforcement
Parallel Enforcement: SEC Authorities and How They Can Impact FDA’s Civil and Criminal Enforcement Luke Cadigan & Sonia Nath ABSTRACT Life sciences companies frequently must determine what information to communicate to investors about key developments in clinical trials or the U.S. Food and Drug Administration’s (FDA) regulatory review process. Although the details of a [...]
Remarks by the Commissioner of Food and Drugs (Open Access)
Food and Drug Law Journal | Volume 78 | Number 1
Remarks by the Director of the Center for Food Safety and Applied Nutrition (Open Access)
Food and Drug Law Journal | Volume 78 | Number 1
Appropriate for the Protection of the Public Health: Why We Need Electronic Nicotine Delivery System Product Standards (Open Access)
Food and Drug Law Journal | Volume 78 | Number 1
